MIMETAS

🚀Catch MIMETAS's expert, Nick Saites, PhD, at #DiscoveryUS2024! 🚀Connect with Nick at the conference to learn how MIMETAS can support your drug discovery efforts with our 3D tissue models. He will also be presenting MIMETAS' latest 3D liver model, developed for fibrosis drug discovery and gene delivery applications. This breakthrough model mimics the liver’s complex, multi-cellular structure, capturing both healthy and diseased states. 🕑 Poster Viewing Times Today: 10:45 AM - Networking Break 1:00 PM - Lunch Break Stop by to chat with Nick and discover how MIMETAS is advancing drug discovery with our services! 🔗 Explore our offerings: https://lnkd.in/ehsm8j9E 🔗 Download the poster: https://lnkd.in/eanzwqam #LiverResearch #DrugDiscovery #Pharma #Biotech #LifeSciences

In this recent publication from our customer, they share valuable insights into how protein-bound uremic toxins affects vascular health, particularly relevant for chronic kidney disease research. The researchers leveraged MIMETAS’s technology to simulate complex human vascular environments, allowing them to observe the damaging effects of p-cresol on endothelial integrity and inflammation. This study highlights the value of physiologically relevant models in revealing disease mechanisms that can be difficult to capture with traditional 2D cultures. Read the article here: https://lnkd.in/eRNVxFU4 At MIMETAS, we’re proud to support our customers with customizable 3D organ models that drive impactful research forward. Interested in how our services can support your research goals? Explore our offerings to see how we can help bring your studies closer to real-world clinical applications. 🔗 https://lnkd.in/ejpzYH2f #CRO #CustomerResearch #VascularHealth #Biotech #Innovation

Streamline your gut toxicity research with OrganoReady® Colon Organoid— an innovative model designed to address the limitations of traditional organoid cultures. This ready-to-use, adult stem cell-derived intestinal model brings you scalability and efficiency, without the need for complex licensing or setup. Whether in your lab or through our in-house services, the OrganoReady® Colon Organoid enables flexible, high-throughput drug screening and safety studies. 👉 Swipe through to learn how this cutting-edge model can advance your research. 🔗 Learn about the OrganoReady Colon Organoid: https://lnkd.in/enab9MzJ #Organoids #Toxicology #GutResearch #Innovation #GastroIntestinalResearch

Microphysiological systems (MPS) are reshaping toxicity testing by delivering more predictive, human-relevant models. At MIMETAS, we’re pushing the boundaries of predictive toxicology with our advanced 3D tissue models, designed to bring human-relevant insights into high-throughput safety screenings. Through our services and ready-to-use models, we enable a detailed exploration of toxicity across key areas: 🧠 Blood-Brain Barrier Toxicity – Assess barrier integrity with HBMEC cells. 🩸 Vascular Toxicity – Monitor endothelial dysfunction using HUVEC models. 🧬 Intestinal Toxicity – Test gut barrier function with colon organoids. 🧪 Neurotoxicity – Detect axonal damage in iPSC-derived motor neuron models. Explore how MIMETAS can enhance your toxicity screening. Download our brochure for details: https://lnkd.in/dQ5fsGYt #MPS #ToxicityTesting #PredictiveToxicology

Our customers' trust is essential to us, and we’re proud to support their groundbreaking research. Today, we're thrilled to share feedback from Dr. Araci Rondon, Senior Researcher at Leiden University Medical Center, on the value of working with MIMETAS in their work. "By collaborating with MIMETAS scientists, we developed a 3D coculture model to study the effects of glioblastoma spheroids on blood coagulation. The OrganoPlate® platform was essential, offering the flexibility to use various tumor sources, which was crucial for our thrombosis research. The advanced 3D coculture capabilities allowed us to closely mimic the tumor microenvironment, including vasculature and perfusion between the tumor and vascular compartments, resulting in more physiologically relevant outcomes. This represents a significant improvement over traditional spheroid and monolayer cultures and enhances our ability to predict thrombus formation, a common challenge in vivo. Furthermore, the platform holds great potential for testing anticoagulant therapies and personalized medicine, with significant implications for treatment development and patient care." Thank you to Dr. Rondon and the team at LUMC for this impactful collaboration! Interested in learning how MIMETAS' 3D tissue models can advance your research? Explore our offerings here: https://lnkd.in/ejpzYH2f #CustomerTestimonial #ThrombosisResearch #3DCellCulture #PersonalizedMedicine #MicrophysiologicalSystems

Join us for an exclusive webinar on Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases, featuring Flavio Bonanini as he explores groundbreaking approaches to modeling disease progression in MASH. Discover how these innovative models are helping to evaluate the efficacy and toxicity of novel treatments, particularly in the context of comorbidities such as obesity and weight loss. 🗓️ Date: October 29 🕒 Time: 4 - 5 PM CEST In this session, you'll gain insights into how MIMETAS' advanced 3D tissue models are driving new breakthroughs in research. Learn how these predictive, human-relevant models are providing unprecedented data on disease mechanisms and therapeutic responses. 🔗Register here: https://lnkd.in/e6JRrGc5 #Webinar #DiseaseModeling #CardiovascularResearch #MetabolicDiseases

🌏 Calling all Asia-Pacific researchers! Join us tomorrow for a live webinar at 4PM JST on "Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context" with Dr. Henriette Lanz, VP of Biology at MIMETAS. Following the presentation, Yoko Ejiri will host a Q&A session, taking questions in both Japanese and English!   Key takeaways: 🔬 Replicate complex tumor microenvironment (TME) dynamics in vitro 💡 Explore angiogenesis, stroma, and immune response interactions 💊 Learn how TME variables influence treatment outcomes 🤝 Discover how partnering with MIMETAS accelerates oncology breakthroughs   🔗 Register now: https://lnkd.in/ep6UgSfP #PhenotypicModeling #CancerResearch #ImmunoOncology #OncologyResearch #DrugDiscovery

Discover how our translatable, ready-to-use 3D human blood vessel model enables high-throughput toxicity assessments, delivering more predictive and reliable results for drug discovery. In this app note, we highlight the versatility of the OrganoReady® Blood Vessel HUVEC by testing with a unique toxin—snake venom—demonstrating its powerful applicability in vascular toxicity research and beyond! Whether you're investigating vascular toxicity or streamlining your drug discovery workflow, this model offers an essential and convenient solution. 📄 Explore the full app note here: https://lnkd.in/gpTuDd-n #DrugDiscovery #3DModels #ToxicityTesting #BloodVesselModel #Innovation

Join Job Komen at PharmaSci 360 this October 23! He'll be presenting our 3D neurite outgrowth assay and how it can be used to evaluate novel cancer therapeutics for peripheral neuropathy.

Traditional drug testing methods often fall short in predicting human responses. What if there was a more reliable way to model human biology and accelerate drug development? A recent publication explores how microphysiological systems (MPS), such as 3D tissue models, offer a more accurate and effective approach to the drug discovery process, including target identification and validation, preclinical evaluation, and clinical trials. By mimicking human biology more closely, these models provide valuable insights that can better predict clinical outcomes. The review article delves into both the challenges and the promising opportunities that MPS technology brings to the field. Read the full article here: https://lnkd.in/ePhqAtqB #DrugDiscovery #MPS #MicrophysiologicalSystems #BiotechInnovation #Pharma